SCHEMBL3623769

SCHEMBL3623769

O=C(Cn1ccc2c(-c3ccnc(Nc4cccc(Cl)c4)n3)cccc21)NCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CAMK2D Q13557 2/20 0.48
▸ CNR2 P34972 2/20 0.47
▸ ABL1 P00519 2/20 0.46
▸ BCR P11274 2/20 0.46
▸ PRKCA P17252 2/20 0.46
▸ PRKCD Q05655 2/20 0.46
▸ EGFR P00533 2/20 0.46
▸ PDGFRB P09619 1/20 0.46
▸ SRC P12931 1/20 0.46
▸ PDGFRA P16234 1/20 0.46
▸ PRKACA P17612 1/20 0.46
▸ PRKACG P22612 1/20 0.46
▸ PRKACB P22694 1/20 0.46
▸ GSK3B P49841 2/20 0.45
▸ CDK2 P24941 3/20 0.44
▸ EIF2AK2 P19525 1/20 0.44
▸ KDR P35968 1/20 0.44
▸ CCNT1 O60563 1/20 0.42
▸ CDK9 P50750 1/20 0.42
▸ ALK Q9UM73 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3621634 0.90 CAMK2D (0.48) CAMK2DABL1BCRPRKCAPRKCD
SCHEMBL3624739 0.89 CDK2 (0.47) CAMK2DABL1BCRPRKCAPRKCD
SCHEMBL3617043 0.89 CAMK2D (0.54) CAMK2DABL1BCRPRKCAPRKCD
SCHEMBL3616916 0.88 CAMK2D (0.52) CAMK2DABL1BCRPRKCAPRKCD
SCHEMBL3611064 0.88 CAMK2D (0.49) CAMK2DABL1BCRPRKCAPRKCD
SCHEMBL3615034 0.87 ABL1 (0.47) CAMK2DCNR2ABL1BCRPRKCA
SCHEMBL3620736 0.86 CCNT1 (0.52) CAMK2DABL1BCRPRKCAPRKCD
SCHEMBL3614692 0.85 ABL1 (0.48) CAMK2DABL1BCRPRKCAPRKCD
SCHEMBL3618140 0.85 CSNK2A1 (0.45) CAMK2DABL1BCRPRKCAPRKCD
SCHEMBL3624563 0.83 EGFR (0.49) CAMK2DABL1BCRPRKCAPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093776-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-04-15 — — US disclosed
US-20100093776-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-04-15 — — US disclosed
US-20100093776-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-04-15 — — US disclosed
EP-2094681-A1 INDOL-4-YL-PYRIMIDINYL-2-YL-AMINE DERIVATIVES AND USE THEREOF AS CYCLIN DEPENDANT KINASE INHIBITORS Novartis AG (CH) 2009-09-02 — — EP disclosed
WO-2008079918-A1 INDOL-4-YL-PYRIMIDINYL-2-YL-AMINE DERIVATIVES AND USE THEREOF AS CYCLIN DEPENDANT KINASE INHIBITORS NOVARTIS AG (CH) 2008-07-03 — — WO disclosed
WO-2008079918-A1 INDOL-4-YL-PYRIMIDINYL-2-YL-AMINE DERIVATIVES AND USE THEREOF AS CYCLIN DEPENDANT KINASE INHIBITORS NOVARTIS AG (CH) 2008-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093776-A1 Organic Compounds and Their Uses OAT, OTC, AOX1 CAMK2D 4474/4885CNR2 2182/4885ABL1 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback